Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Natera, a leader in cell-free DNA testing, has expanded its laboratory facility in Austin, Texas, increasing its test processing capacity. The new 70,000 square foot facility features advanced automated equipment, which is expected to lower costs and improve operational continuity. Natera targets significant growth in markets exceeding a $25 billion dollar opportunity, having processed over three million medical tests to date. This expansion positions Natera to better serve patients and capitalize on future market demands.
Natera, Inc. (NASDAQ: NTRA) has announced the initiation of patient enrollment in two clinical trials: CIRCULATE-Japan and BESPOKE CRC. The CIRCULATE-Japan trial is a multi-center study with 2,500 participants focused on ctDNA-guided treatment strategies for resectable colorectal cancer (CRC) in Japan. Similarly, BESPOKE CRC aims to enroll over 1,000 patients, assessing the impact of blood-based testing for early relapse detection. Both trials highlight the growing interest and potential of Signatera technology, which may improve treatment outcomes for CRC patients globally.
Natera, Inc. (NASDAQ: NTRA) has filed a patent infringement lawsuit against Progenity, Inc. in the U.S. District Court for the Western District of Texas. The suit claims that Progenity's non-invasive prenatal test infringes on six patents held by Natera. These include U.S. Patents 9,228,234; 9,424,392; 10,227,652; 10,240,202; 10,266,893; and 10,522,242. Natera is seeking both injunctive relief and monetary damages.